BillionToOneBLLN +2.04%13 Interest Coverage is 1,783.40 as of Mar. 2026, which is 957% above its 10-year median of 168.66. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 94 Medical Diagnostics & Research companies, BillionToOne ranks better than 92.55% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. BillionToOne's
Operating Income
for the
three
months ended in Mar. 2026 was $17.8 Mil. BillionToOne's Interest Expense for the
three
months ended in Mar. 2026 was $-0.0 Mil.
BillionToOne's interest coverage for the quarter that ended in Mar. 2026 was 1,783.40.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. BillionToOne Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for BillionToOne's Interest Coverage or its related term are showing as below:
BLLN'
s Interest Coverage Range Over the Past 10 Years
Min: 168.66 Med: 168.66 Max: 556.49
Current: 556.49
BLLN's Interest Coverage is ranked better than 92.55% of 94
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.155
vs BLLN: 556.49
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
BillionToOne Interest Coverage Related Terms
BillionToOne Interest Coverage Historical Data
* Premium members only.
The historical data trend for BillionToOne's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BLLN vs SHC, VCYT, RDNT: Interest Coverage Comparison
For the Diagnostics & Research subindustry, BillionToOne's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Interest Coverage distribution charts can be found below:
* The bar in red indicates where BillionToOne's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a Interest Coverage of 1,783.40 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BillionToOne and its competitors. This is 957% above median its historical median of 168.66. Over the past decade, BillionToOne's Interest Coverage has ranged from 168.66 to 556.49. According to the industry distribution chart, BillionToOne ranks #7 out of 94 companies in the Medical Diagnostics & Research industry, placing it in the top 7.4%.
Is BillionToOne's Interest Coverage too high?
BillionToOne's current Interest Coverage of 1,783.40 is 957% above median its 10-year median of 168.66. Over the past 10 years, this metric has ranged from a low of 168.66 to a high of 556.49. The Medical Diagnostics & Research industry median Interest Coverage is 9.16. BillionToOne's value of 1,783.40 is 19380.1% above this industry median. Based on the distribution chart, BillionToOne ranks #7 out of 94 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Interest Coverage compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #7 out of 94 companies for Interest Coverage. This places BillionToOne in the top 7% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 9.16. BillionToOne's value of 1,783.40 is 19380.1% above this benchmark. Historically, BillionToOne's own Interest Coverage has ranged from 168.66 to 556.49 over the past decade. While the company's 10-year median is 168.66 vs. the industry median of 9.16, BillionToOne has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.16, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current Interest Coverage of 1,783.40 is 19380.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current Interest Coverage is 1,783.40, which is 957% above median its own 10-year median of 168.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Interest Coverage of 1,783.40. The current Interest Coverage is 1,783.40, which is 957% above median its 10-year median of 168.66 and 19380.1% above the Medical Diagnostics & Research industry median of 9.16. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BillionToOne (BLLN), the current Interest Coverage is 1,783.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 